New onset atrial fibrillation is associated with elevated galectin-3 levels

International Journal of Cardiology

Volumn 223, Issue , 2016, Pages 48-49

  Chen, D ^a   Procter, N ^a   Goh, V ^a   Liu, S ^a   Chua, S J ^a   Assadi Khansari, B ^a   Stewart, S ^b   Horowitz, J D ^a   Sverdlov, A L ^a   Ngo, D T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

Atrial fibrillation; Chronic atrial fibrillation; Galectin 3; New onset atrial fibrillation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE ASSESSMENT; CHA2D2S VASC SCORE; CHRONIC ATRIAL FIBRILLATION; CHRONICITY; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW-ONSET ATRIAL FIBRILLATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ATRIAL FIBRILLATION; BLOOD; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; PREDICTIVE VALUE; PROGNOSIS;

AGED; ATRIAL FIBRILLATION; DISEASE PROGRESSION; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; PATIENT ACUITY; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84981335318     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.08.172     Document Type: Article

References (10)

1. [1] Ball, J., et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int. J. Cardiol. 167:5 (2013), 1807–1824.
2. [2] Heymans, S., et al. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. Eur. J. Heart Fail. 17:8 (2015), 764–771.
3. [3] Yu, L., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 6:1 (2013), 107–117.
4. [4] Szadkowska, I., et al. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol. J. 20:6 (2013), 577–582.
5. [5] Yalcin, M.U., et al. The association of serum galectin-3 levels with atrial electrical and structural remodeling. J. Cardiovasc. Electrophysiol. 26:6 (2015), 635–640.
6. [6] Takemoto, Y., et al. Galectin-3 regulates atrial fibrillation remodeling and predicts catheter ablation outcomes. JACC Basic Transl. Sci. 1:3 (2016), 143–154.
7. [7] Sonmez, O., et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med. Sci. Monit. 20 (2014), 463–470.
8. [8] Zakeri, R., et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ. Heart Fail. 7:1 (2014), 123–130.
9. [9] Ho, J.E., et al. Galectin 3 and incident atrial fibrillation in the community. Am. Heart J. 167:5 (2014), 729–734 e1.
10. [10] Szadkowska, I., et al. The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers 18:8 (2013), 655–659.